RNA 치료 시장 : RNA 유형, 전달 시스템, 치료법, 응용 분야, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The RNA Therapy Market is projected to grow by USD 22.68 billion at a CAGR of 8.71% by 2032.

RNA Therapy Market Overview

RNA therapy has moved from a specialized scientific platform into a core modality for modern biopharmaceutical development. The field spans messenger RNA therapeutics, small interfering RNA drugs, antisense oligonucleotides, RNA interference therapies, aptamers, and guide RNA-enabled gene editing approaches. Validated approvals, including nusinersen for spinal muscular atrophy, patisiran for hereditary transthyretin-mediated amyloidosis, inclisiran for LDL-C reduction, and mRNA vaccines for COVID-19, demonstrate that RNA-based medicines can deliver clinically meaningful outcomes across rare diseases, infectious diseases, cardiometabolic disorders, and oncology.

The RNA therapy market is being shaped by advances in lipid nanoparticles, GalNAc conjugation, chemically modified nucleotides, scalable synthesis, and improved analytical characterization. Industry attention is increasingly focused on delivery beyond the liver, durability of response, repeat dosing safety, cold-chain optimization, and regulatory readiness for platform-based product families. For decision-makers, RNA therapeutics represent both a high-growth innovation segment and a complex operating environment requiring disciplined evidence generation, manufacturing resilience, and differentiated clinical strategy.

Transformative Shifts in the RNA Therapy Landscape

The RNA therapy landscape is undergoing a structural shift from single-product innovation toward programmable medicine platforms. The success of mRNA vaccines accelerated investment in RNA design, formulation, and manufacturing infrastructure, while approved siRNA and antisense therapies validated chronic and rare disease applications. Developers are now expanding from hepatic targets into muscle, central nervous system, lung, immune, and tumor microenvironment delivery, where tissue specificity remains a central competitive differentiator.

Another major shift is the convergence of RNA therapeutics with precision medicine. Biomarker-defined populations, genetic diagnostics, newborn screening, and companion testing are improving patient identification for RNA-based interventions. At the same time, regulatory agencies are increasingly familiar with oligonucleotide chemistry, platform comparability, and manufacturing controls, creating a more mature path for developers that can demonstrate quality, safety, and reproducible clinical benefit.

Cumulative Impact of Artificial Intelligence on RNA Therapy

Artificial intelligence is increasingly influencing RNA therapy discovery, design, and development. AI-enabled models support target prioritization, off-target risk assessment, sequence optimization, codon usage design, immune-stimulation prediction, and lipid nanoparticle formulation screening. The FDA has reported a sharp rise in drug and biologic submissions containing AI or machine learning components, signaling that computational approaches are becoming embedded in regulated development workflows.

The cumulative impact of AI is most visible in cycle-time compression and experiment prioritization rather than in replacing biological validation. For RNA therapeutics, AI can help narrow candidate libraries, improve manufacturability, identify toxicity signals earlier, and integrate multi-omics evidence for patient stratification. Industry leaders that combine AI with high-quality wet-lab data, traceable model governance, and regulatory documentation are better positioned to improve probability of success while maintaining scientific credibility.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

North America remains a leading hub for RNA therapy innovation, supported by the United States biotechnology ecosystem, FDA experience with mRNA vaccines, siRNA drugs, antisense oligonucleotides, and advanced therapy regulatory pathways. Canada contributes through academic research, clinical trial participation, public genomics initiatives, and health system infrastructure, while Mexico is increasingly relevant for regional healthcare access discussions, clinical operations, and cross-border supply-chain planning.

Europe benefits from the European Medicines Agency, the Horizon Europe research framework, national genomics strategies, and strong biomanufacturing clusters across Germany, France, the United Kingdom, Italy, and Spain. Asia-Pacific is expanding through China's large clinical trial base, Japan's mature regulatory and pharmaceutical environment, South Korea's biologics manufacturing strength, India's cost-efficient scientific talent and vaccine production experience, and Australia's active early-stage clinical research incentives. Latin America, led by Brazil and Mexico, is gaining attention for infectious disease experience, diverse patient recruitment, and public health networks, while the Middle East and Africa are emerging through vaccine access programs, genomics initiatives, healthcare modernization, and gradual investments in local biomanufacturing capacity.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7 & NATO

ASEAN countries are building relevance in RNA therapy through expanding clinical research networks, vaccine manufacturing ambitions, and public health preparedness programs. Singapore plays a regional role in biomedical R&D and advanced manufacturing, while Thailand, Malaysia, Indonesia, the Philippines, and Vietnam offer growing patient access and trial-enrollment potential when regulatory alignment, pharmacovigilance, reimbursement readiness, and cold-chain capacity are addressed.

The European Union provides harmonized regulatory pathways, cross-border research funding, data protection rules, and strong intellectual property structures that support RNA therapeutic development. GCC countries are investing in precision medicine, genomics, tertiary care, and pharmaceutical localization as part of economic diversification strategies. BRICS nations are important for scientific and patient scale, with China and India offering large research and manufacturing bases, Brazil and South Africa contributing regional access and public health perspectives, and Russia maintaining scientific capacity amid external constraints. G7 markets remain central to premium reimbursement, advanced clinical adoption, regulatory precedent, and post-approval evidence generation, while NATO member countries overlap substantially with high-income biopharma markets and resilient medical supply-chain priorities.

Key Country Insights for RNA Therapy Growth

The United States leads RNA therapy commercialization through deep venture capital markets, FDA-approved RNA medicines, advanced clinical trial infrastructure, and a dense network of biotech developers, contract manufacturers, and academic centers. Canada supports translational research, genomics, and clinical collaboration, while Mexico is an important North American market for patient access and regional healthcare partnerships. Brazil anchors Latin America with a large population, established clinical research capacity, and public health experience relevant to vaccine and infectious disease platforms.

In Europe, the United Kingdom, Germany, and France are prominent in RNA research, regulatory science, and pharmaceutical development, while Italy and Spain strengthen clinical trial networks, specialist hospitals, and hospital-based adoption. Russia maintains scientific expertise but faces geopolitical, regulatory, and supply-chain constraints. In Asia-Pacific, China is scaling RNA research, clinical development, and manufacturing; India offers scientific talent, vaccine infrastructure, and cost-efficient production potential; Japan provides mature regulatory and pharmaceutical capabilities; Australia is recognized for early-phase clinical research and favorable trial operations; and South Korea is advancing biologics manufacturing, vaccine platforms, and global CDMO relevance.

Actionable Recommendations for RNA Therapy Industry Leaders

Industry leaders should prioritize delivery innovation, because tissue targeting remains the most important technical constraint for RNA therapy expansion beyond liver-directed programs. Investment in lipid nanoparticle engineering, ligand conjugation, endosomal escape technologies, and local delivery approaches should be paired with rigorous safety pharmacology, biodistribution studies, immunogenicity assessment, and repeat-dose monitoring.

Organizations should also strengthen CMC strategy early. Scalable oligonucleotide synthesis, impurity control, analytical comparability, sterile fill-finish capacity, raw material security, and cold-chain resilience can determine development timelines as much as clinical efficacy. Organizations should build regulatory engagement plans that address platform data, immunogenicity, repeat dosing, pharmacovigilance, and long-term follow-up. Partnerships with diagnostics providers, AI-enabled discovery platforms, CDMOs, and regional clinical networks can accelerate development while reducing risk.

Research Methodology

This executive summary is developed through secondary research and expert synthesis of publicly available, verifiable sources, including regulatory approvals and guidance from the FDA and EMA, clinical trial registries, peer-reviewed literature, public health agency updates, patent databases, and recognized biotechnology industry disclosures. The analysis emphasizes confirmed product approvals, documented platform advances, regional policy signals, and observable investment and manufacturing trends.

The methodology applies triangulation across regulatory, scientific, commercial, and geographic datasets to identify durable market patterns rather than speculative claims. Each insight is assessed for relevance to RNA therapeutics, including mRNA therapy, siRNA drugs, antisense oligonucleotides, RNA interference, delivery systems, GMP manufacturing, clinical adoption, and regional access dynamics. The resulting perspective is designed to support planning, market positioning, and digital communication.

Conclusion

RNA therapy is now an established and expanding therapeutic category, supported by approved medicines, validated delivery technologies, and increasing regulatory familiarity. The sector's next phase will depend on expanding delivery to new tissues, improving durability and tolerability, reducing manufacturing complexity, and demonstrating value in large and genetically defined patient populations.

Organizations that combine strong science, platform governance, AI-enabled development, regional access planning, and manufacturing excellence will be best positioned to compete. As RNA therapeutics continue to reshape rare disease, infectious disease, oncology, neurology, and cardiometabolic care, the market offers substantial opportunity for developers capable of converting programmable biology into reliable, accessible, and clinically differentiated medicines.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. RNA Therapy Market, by RNA Type

• 7.1. Messenger RNA
  • 7.1.1. Circular mRNA
  • 7.1.2. Conventional mRNA
• 7.2. Small Interfering RNA
  • 7.2.1. Unmodified siRNA
  • 7.2.2. Chemically Modified siRNA
• 7.3. Antisense Oligonucleotides
• 7.4. MicroRNA
• 7.5. Ribozymes

8. RNA Therapy Market, by Delivery System

• 8.1. Exosomes
• 8.2. Lipid Nanoparticles
• 8.3. Polymer Carriers
• 8.4. Viral Vectors

9. RNA Therapy Market, by Therapeutic Modality

• 9.1. Gene Silencing
• 9.2. Gene Replacement
• 9.3. Protein Expression Induction
• 9.4. Splicing Modulation
• 9.5. Immune System Modulation

10. RNA Therapy Market, by Application Area

• 10.1. Cardiovascular Diseases
• 10.2. Genetic Disorders
• 10.3. Infectious Diseases
  • 10.3.1. Bacterial Infections
  • 10.3.2. Viral Infections
• 10.4. Metabolic Disorders
• 10.5. Neurological Disorders
• 10.6. Oncology
  • 10.6.1. Hematological Malignancies
  • 10.6.2. Solid Tumors
• 10.7. Rare Diseases
  • 10.7.1. Gaucher Disease
  • 10.7.2. Neuromuscular Disorders
  • 10.7.3. Sickle Cell Disease

11. RNA Therapy Market, by End User

• 11.1. Biotechnology Companies
• 11.2. Hospitals & Clinics
• 11.3. Pharmaceutical Companies
• 11.4. Research Institutes

12. RNA Therapy Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. RNA Therapy Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. RNA Therapy Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Alnylam Pharmaceuticals, Inc.
• 16.2. Arbutus Biopharma Corporation
• 16.3. Arrowhead Pharmaceuticals, Inc.
• 16.4. AstraZeneca PLC
• 16.5. Benitec Biopharma Limited
• 16.6. Biogen Inc.
• 16.7. BioNTech SE
• 16.8. Cartesian Therapeutics, Inc.
• 16.9. Cenix BioScience GmbH
• 16.10. Deep Genomics
• 16.11. Eli Lilly and Company
• 16.12. F. Hoffmann-La Roche Ltd
• 16.13. GSK PLC
• 16.14. Ionis Pharmaceuticals, Inc.
• 16.15. MiNA Therapeutics Limited
• 16.16. Moderna, Inc.
• 16.17. NeuBase Therapeutics, Inc.
• 16.18. Nordic Nanovector ASA
• 16.19. Novartis AG
• 16.20. Novo Nordisk A/S
• 16.21. Nutcracker Therapeutics, Inc.
• 16.22. Pfizer Inc.
• 16.23. ProQR Therapeutics N.V.
• 16.24. Sanofi S.A.
• 16.25. Silence Therapeutics PLC
• 16.26. Sirnaomics, Inc.
• 16.27. Suzhou Abogen Biosciences Co., Ltd.
• 16.28. Triplet Therapeutics, Inc.